The progress of targeted therapy in advanced gastric cancer
Miao-zhen Qiu and Rui-hua Xu*

Abstract
Although palliative chemotherapy has been shown to prolong survival and improve quality of life, the survival of advanced gastric cancer (AGC) patients remains poor. With the advent of targeted therapy, many molecular targeted agents have been evaluated in clinical studies. Trastuzumab, an anti-HER2 monoclonal antibody, has shown activity against HER2-positive AGC and becomes the first targeted agent approved in AGC. Drugs that target epidermal growth factor receptor, including monoclonal antibody and tyrosine kinase inhibitor, do not bring survival benefit to patients with AGC. Additionally, vascular endothelial growth factor inhibitors are also under investigation. Ramucirumab has shown promising result. Other targeted agents are in preclinical or early clinical development, such as mammalian target of rapamycin inhibitors and c-MET inhibitors.

Introduction
Approximately one million people are diagnosed each year with gastric cancer, making it the fourth most common cancer and the second leading cause of cancer related death worldwide with an estimated 800,000 deaths caused by the disease [1]. The incidence of gastric cancer varies widely according to geographic region and is particularly common in eastern Asia [2]. According to the 2012 Chinese cancer registry annual report, gastric cancer is the third most common cancer and the second leading cause of cancer related death in China [3]. The only treatment that offers a potential cure is complete resection of the tumor. However, in most of countries, the majority of patients are diagnosed at advanced stages and have a poor prognosis. Though first-line chemotherapy for advanced gastric cancer (AGC) prolongs overall survival (OS) and improves quality of life compared with best supportive care (BSC). The median survival of advanced gastric cancer patients who received palliative chemotherapy is approximately 7 to 11 months [4-8]. In 2010, trastuzumab (Herceptin, Roche, Basel, Switzerland), a recombinant humanized monoclonal antibody that targets human epidermal growth factor receptor-2 (HER2), had already been confirmed to be effective when combined with chemotherapy in HER2-positive AGC patients [9]. Trastuzumab is the first targeted agent that gets the indication in AGC, but it is not the only targeted agents which have tried their applications in AGC. The other therapeutic strategies include: epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, hepatocyte growth factor (HGF) and its receptor c-MET pathway inhibitor, mammalian target of rapamycin (m-TOR) inhibitor et al. This review will focus on the recent progress in targeted agents for the treatment of AGC (Table 1).

EGFR-signaling pathway
EGFR exists on the cell surface and is part of the family of TK receptor including HER2. EGFR overexpression has been reported in approximately 30% to 50% of gastric cancers and is associated with poor prognosis [10-14].

Anti-HER2 monoclonal antibodies
HER2, a transmembrane tyrosine kinase (TK) receptor, is the preferred heterodimerization partner of the other HER family members (HER1 or EGFR, HER3 and HER4). The HER2-HER3 heterodimer plays a critical role in oncogenic transformation in HER2-driven tumors [15,16]. In breast cancer, amplification and overexpression of the HER2 gene is associated with poor outcomes, higher mortality, and higher recurrence as well as...
| NCT code/trial name | Drugs | Setting | Masking | Primary endpoint | Arm | Status | Results |
|---------------------|-----------------|---------|---------|-----------------|-----|--------|---------|
| PhasellIToGA/NCT01041404 | HER2 inhibitor | Trastuzumab | First line | Double blind | OS | Cisplatin + fluoropyrimidine + Trastuzumab vs. Placebo | Finished | Positive |
| PhasellINTC01774786 | Pertuzumab | First line | Double blind | OS | Trastuzumab + cisplatin + fluoropyrimidine + Pertuzumab vs. Placebo | Ongoing | Unknown |
| Phase III/NIHCT01641939 | T-DM1 | Second line | Open label | OS | T-DM1 vs. Taxane | Ongoing | Unknown |
| Phasell TTYTAN/NCT00486954 | Lapatinib | Second line | Open label | OS | Lapatinib vs. Paclitaxel | Finished | Negative |
| Phasell LOGIC/NCT00680901 | Lapatinib | First line | Double blind | OS | Capecitabine + oxaliplatin + Lapatinib vs. Placebo | Finished | Negative |
| PhasellEXPAND/NCT00678535 | EGFR Inhibitors | Cetuximab | First line | Open label | PFS | Capecitabine and cisplatin vs. Cetuximab | Finished | Negative |
| PhasellREAL-3/NCT01234324 | Panitumumab | First line | Open label | Frequency of pT3/T4 categories after surgery | EOX (epirubicin/oxaliplatin/capecitabine) | Ongoing | Unknown |
| PhasellAVAGAST/NCT00548548 | VEGF inhibitors | Bevacizumab | First line | Double blind | OS | Capecitabine + cisplatin vs. Bevacizumab | Finished | Negative |
| Phasell REGARD/NCT00917384 | Ramucirumab | Second line | Double blind | OS | and 5FU + Ramucirumab vs. Placebo | Finished | Positive |
| PhasellRAINBOW/NCT01170663 | Ramucirumab | Second line | Double blind | OS | Paclitaxel + Ramucirumab vs. Placebo | Ongoing | Unknown |
| PhasellINTC01246960 | Ramucirumab | First line | Double blind | PFS | mFOLFOX6+ Ramucirumab vs. Placebo | Ongoing | Unknown |
| PhasellINTC00970138 | Apatinib | Third line | Double blind | PFS | Placebo vs. Apatinib | Finished | Positive |
| PhasellINTC01512745 | Apatinib | Third line | Double blind | PFS | Placebo vs. Apatinib | Ongoing | Unknown |
| PhasellINTC01747551 | Afibercept | First line | Double blind | PFS | mFOLFOX6 + Afibercept vs. Placebo | Ongoing | Unknown |
| PhasellINTC01152645 | c-MET inhibitor | Tivantinib (ARQ197) | Second/third line | Open label | DCR | Tivantinib | Finished | Modest efficacy |
| PhasellINTC01662869 | Onartuzumab | First line | Double blind | OS | mFOLFOX6 + Onartuzumab vs. Placebo | Ongoing | Unknown |
| PhasellGRANITE-1/NCT00879333 | m-TOR inhibitor | Everolimus (RAD001) | Second/third line | Double blind | OS | Everolimus vs. Placebo | Finished | Negative |

**Abbreviation:** HER2 human epidermal growth factor receptor-2, OS overall survival, EGFR epidermal growth factor receptor, PFS progression free survival, VEGF vascular endothelial growth factor, BSC best supportive care, DCR disease control rate, m-TOR mammalian target of rapamycin.
metastasis rate [17-19]. However, the association between HER2 status and prognosis in gastric cancer remains controversial. In a few studies a correlation between HER2 amplification or overexpression and favorable survival was shown [20,21]. In a retrospective analysis from four Chinese clinical centers, the HER2 status of 726 gastric cancer patients with all stages was detected. They found that HER2 was not a prognostic factor for gastric cancer patients [22]. A systematic analysis of data from the literature indicated that there was a clear trend towards a potential role for HER2 as a negative prognostic factor in gastric cancer patients [23].

**Trastuzumab**

In the ToGA trial, the addition of trastuzumab to chemotherapy significantly improved OS compared with chemotherapy alone in patients with HER2-positive AGC. The HER2 positive rate was 22.1% in this study. The median OS was improved significantly in the trastuzumab arm compared with the control arm [13.5 vs. 11.1 months, P = 0.0048; hazard ratio (HR), 0.74; 95% confidence interval (CI), 0.60 to 0.91]. In subgroup analysis, the patients with HER2 immunohistochemistry (IHC) 2+/fluorescence in situ hybridization + or IHC 3+ had a longer OS compared with the chemotherapy-alone arm (16 months vs. 11.8 months). Moreover, the addition of trastuzumab to chemotherapy in the ToGA trial was well-tolerated, with no differences in the incidence of grade 3 or 4 adverse events (AEs) between the two groups [9]. Based on the result of ToGA study, trastuzumab with chemotherapy was recommended for HER2 overexpressing AGC (category 1 for combination with cisplatin and fluoropyrimidine; category 2B for combination with other chemotherapy agents; not recommended for use with anthracyclines) in the national comprehensive cancer network guidelines of gastric cancer version 2 2012.

**Pertuzumab**

Pertuzumab is a monoclonal antibody that prevents dimerization of HER2 with other HER family receptors [24]. Its efficacy in combination with trastuzumab in HER2-positive metastatic breast cancer patients has been demonstrated in phase III clinical trials [25,26]. At the 2013 American Society of clinical oncology (ASCO) meeting, the result of an international phase III study was reported. This was a double-blind, placebo-controlled, randomized phase III study and it was designed to evaluate efficacy and safety of pertuzumab + trastuzumab + chemotherapy in patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer. In this study, HER2-positive metastatic gastric cancer patients were randomized 1:1 to receive trastuzumab + cisplatin + fluoropyrimidine + pertuzumab vs. placebo. Primary endpoint was OS. The result of this study is worth looking forward to [27].

**T-DM1**

T-DM1 is an antibody-drug conjugate in which trastuzumab is conjugated to a cytotoxic compound, emtansine [28]. Upon binding of the trastuzumab moiety to HER2, T-DM1 is internalized into the tumor cell, releasing the DM1 moiety, which inhibits microtubules. A trial (NCT01641939) is now ongoing to examine the efficacy and safety of T-DM1 compared with standard taxane therapy in patients with HER2-positive gastric cancer in second line setting. In this study, patients will be randomized to one of the three groups, 3.6 mg/kg T-DM1 every 3 weeks, 2.4 mg/kg T-DM1 every week, or standard taxane therapy (Taxol 80 mg/m2/wk or docetaxol 75 mg/m2 q3wk), for at least four cycles (12 weeks). Planned endpoints include OS.

The results of these studies are eagerly awaited to examine the efficacy of this approach in patients with HER2-positive AGC.

**HER-2 TKI**

Lapatinib, a reversible dual TKI that affects both HER2 and EGFR, has also been clinically shown to be active against HER2-positive breast cancer as a monotherapy and in combination with capecitabine [29]. The TYTAN study compared lapatinib and paclitaxel with paclitaxel alone in patients with HER2-positive metastatic gastric cancer in a second line setting. The primary endpoint of the study was OS. Though lapatinib showed efficacy in HER2 IHC 3+ subgroups, this study did not show an improvement in OS. These results indicated that the definition of HER2-positive AGC was very important for the development of new anti-HER2 agents [30]. At the 2013 ASCO meeting, lapatinib in combination with capecitabine plus oxaliplatin in HER2-positive advanced or metastatic gastroesophageal adenocarcinoma, the LOGiC trial was reported. Primary endpoint of improving OS was not met. The median OS in the lapatinib group and the control group was 12.2 months and 10.5 months, respectively, P = 0.3492. Improved OS was seen in Asian patients and patients under 60 years old. Secondary efficacy endpoints of progression free survival (PFS), response rate (RR) and duration of response were improved with addition of lapatinib. No new safety signal was identified, but increased toxicity was seen with the addition of lapatinib to capecitabine and oxaliplatin, particularly diarrhea and skin toxicity [31]. Prior to this study, there was no evidence to support the use of lapatinib in HER2-positive AGC.
Cetuximab
Manageable and expected safety profiles with substantial activities were reported in phase II studies of cetuximab plus various first line chemotherapy regimens in patients with AGC [32-35].

In a prospective multi-center biomarker-oriented phase III trial using cetuximab with folfiri as first-line treatment in AGC, patients received weekly cetuximab (400 mg/m² on day 1, subsequently 250 mg/m²) plus irinotecan and a 24-hour continuous infusion of folinic acid and 5-fu on days 1, 8, 15, 22, 29 and 36 of a 50-day cycle, until disease progress (PD). In 48 assessable patients, the overall response rate was 46% and disease control rate (DCR) was 79%. Median PFS and OS were 9.0 months (95% CI 7.1-15.6) and 16.5 months (95% CI 11.7-30.1), respectively. No obvious cetuximab-related side effects were recorded in this study. However, despite a favorable result in these phase II trials, the results of a randomized phase III trial comparing cetuximab in combination with capcitabine and cisplatin with chemotherapy alone (EXPAND) were negative in this study. In 904 patients were randomly assigned (1:1) to receive first-line chemotherapy (capcitabine and cisplatin) with or without cetuximab (400 mg/m² on day 1, subsequently 250 mg/m²). The primary endpoint was PFS. The median PFS and OS were 4.4 and 9.4 months, respectively, in patients assigned to cetuximab plus chemotherapy compared with 5.6 and 10.7 months in patients receiving chemotherapy, respectively (PFS, p = 0.3158; OS, p = 0.9547) [36]. Addition of cetuximab provided no additional benefit to chemotherapy alone in the first-line treatment of advanced gastric cancer.

Panitumumab
Panitumumab is a fully human, immunoglobulin G2 monoclonal antibody directed against the EGFR. In metastatic colorectal cancer, panitumumab has monotherapy activity in patients with chemotherapy refractory diseases and, when added to chemotherapy, can improve PFS in KRAS oncogene wide type patients in the first-line treatment of advanced gastric cancer.

Panitumumab group was associated with increased incidence of grade 3-4 diarrhoea, rash, mucositis and hypomagnesaemia but reduced incidence of haematological toxicity [37].

Based on the results above, no more clinical trials of anti-EGFR monoclonal antibody in gastric cancer will be carried out. Moreover, neither erlotinib nor gefitinib showed activity in anti-gastric cancer in phase III studies.

VEGF-signaling pathway
Tumor angiogenesis and metastasis are strongly linked with angiogenesis in most solid tumors. VEGF is a key mediator of physiologic and pathologic angiogenesis [38].

Anti-VEGF monoclonal antibody
Preclinical studies showed that bevacizumab (Avastin, Genentech/Roche, San Francisco, CA/Basel, Switzerland), a monoclonal antibody targeting VEGF-A, resulted in tumor growth inhibition when given as monotherapy or in combination with cytotoxic agents [39]. In patients with gastric cancer, VEGF expression has been linked to tumor aggressiveness and poor prognosis [14,40-42]. Several phase II trials combining bevacizumab with different chemotherapeutic compounds were conducted on treatment-naïve or pretreated patients with AGC or GEJ cancers [43-45]. AVAGAST was a prospective, randomization, double-blind, placebo-controlled phase III clinical trial comparing capcitabine/cisplatin with or without bevacizumab as first-line therapy in 774 patients with AGC [46]. The primary endpoint was OS. Although AVAGAST did not reach its primary endpoint (OS: 12.1 vs. 10.1 months for the bevacizumab and placebo groups (HR, 0.87; P = 0.1002)), both median PFS (6.7 vs 5.3 months; HR, 0.80; 95% CI, 0.68 to 0.93; P = 0.0037) and RR (46.0% v 37.4%; P = 0.0315) were significantly improved with bevacizumab versus placebo. The incidence of grades 3 to 4 AEs potentially related to bevacizumab was similar in both arms.

Anti-VEGFR monoclonal antibody
Ramucirumab (IMC-1121B; ImClone Systems, New York, NY) is a fully human immunoglobulin G1 monoclonal antibody that binds with high affinity to the extracellular VEGF-binding domain of VEGFR-2. Phase I clinical trials demonstrated its objective antitumor activity and antiangiogenic effects over a wide range of dose levels, suggesting that ramucirumab may have a favorable therapeutic index in treating malignancies amenable to VEGFR-2 inhibition [47]. REGARD study [48] is a phase III, randomized, double-blinded trial of ramucirumab in the treatment of AGC or GEJ adenocarcinoma in second line setting. Patients were randomized 2:1 to receive ramucirumab (8 mg/kg IV) plus BSC or placebo plus BSC every 2 weeks until PD, unacceptable toxicity, or death. The primary endpoint was OS. The HR for OS was 0.776 (95% CI, 0.603-0.998; P = 0.0473). Median OS was 5.2 months for ramucirumab group and 3.8 months for placebo group. The HR for PFS was 0.483 (95% CI, 0.376-0.620; p < 0.0001). Median PFS was 2.1 and 1.3
VEGFR TKI
Apatinib (YN968D1) is a small-molecular TKI agent targeting at VEGFR [49]. In a randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib in patients with metastatic gastric carcinoma, patients were randomized to receive placebo or apatinib (placebo vs. apatinib at 850 mg once a day vs. 425 mg twice a day) [50]. The primary endpoint was PFS. The respective survival rates were as follows: median PFS, 1.4 months vs. 3.4 months vs. 3.4 months; median OS, 2.5 months vs. 4.8 months vs. 4.3 months. Common AEs included hypertension and hand-foot syndrome. Based on this result, a randomized, double blinded, placebo-controlled multicenter phase III study in a third-line setting in AGC is currently being conducted in China. Patients are scheduled to receive apatinib 850 mg qd or placebo until PD or intolerable toxicity or patients’ withdrawal of consent. The primary endpoint is PFS (NCT01512745).

VEGF trap
Aflibercept (VEGF Trap, Sanofi, Paris France; and Regeneron, Tarrytown, NY, USA) is a recombinant fusion protein consisting of extracellular domains of the human VEGFR fused to the Fc portion of human immunoglobulin G1 [51-53]. Its biological affinity for VEGF is reported to be significantly higher than that of bevacizumab [54]; however, there are no preclinical data to suggest its increased efficacy in AGC.

Aflibercept has recently been approved by the Food and Drug Administration for patients with treatment-resistant colorectal cancer. A phase II clinical trial to test the safety and effectiveness of aflibercept in combination with mFOLFOX6 compared to mFOLFOX6 alone in patients with AGC is ongoing.

Other targeted agents
MET inhibitor
c-Met is a proto-oncogene that encodes a protein known as hepatocyte growth factor receptor (HGFR) [55,56]. It stimulates cell scattering, invasion, protection from apoptosis and angiogenesis [57]. Upon HGF stimulation, MET induces MET kinase catalytic activity which triggers transphosphorylation of the tyrosine (Tyr) 1234 and Tyr 1235, thus initiating a whole spectrum of biological activities driven by MET. A high level of c-Met expression has been correlated with poor survival in patients with gastric cancer [58].

c-Met inhibitors include monoclonal antibodies and small molecules that inhibit the enzymatic activity of the c-Met TK. There are basically two classes of c-Met inhibitors, ATP competitive and ATP non-competitive inhibitor. ATP competitive inhibitors are further divided into two classes; class I (SU-11274-like) and class II (AM7-like) on the basis of different types of binding and a third group of noncompetitive ATP inhibitor that binds in a different way to the other two [59,60].

Elevated expressions of c-MET and its ligand, HGF, have been frequently found in gastric cancer, and are associated with a more aggressive disease [61,62]. Tivantinib is a selective, non-ATP competitive, small-molecule inhibitor of c-MET and is under development in several cancers. In a single-arm phase II study, the efficacy of tivantinib monotherapy in Asian patients with previously treated AGC was evaluated [63]. Tivantinib was daily administered 360 mg bid orally. The primary endpoint was DCR. No objective response was observed, and DCR was 36.7% (11/30 patients). Median PFS was 43 (95% CI: 29.0-92.0) days. There is no treatment-related death and novel safety concern. Tivantinib as a monotherapy showed a modest efficacy in previously treated AGC, and further trial testing in combination would be warranted in AGC.

Onartuzumab is a humanized mAb directed against HGF. A randomized, phase III, multicenter, double-blind, placebo-controlled study evaluating the efficacy and safety of onartuzumab in combination with mFOLFOX6 in patients with metastatic Her2-negative, c-Met-positive gastroesophageal cancer is now ongoing.

m-TOR inhibitor
mTOR is a key protein kinase that regulates cell growth and proliferation, cellular metabolism and angiogenesis [64]. Mutations in these components result in inappropriate mTOR activation [64]. The mTOR pathway has been shown to be frequently dysregulated in a variety of human cancers, including gastric cancer [65]. Overexpression of the mTOR downstream effectors elf4E and 4E binding protein 1 (4E-BP1) was shown in GI cancer cells [64]. Everolimus (RAD001) is an oral inhibitor of m-TOR, which is downstream of the Akt pathway. Everolimus reduced 4E-BP1 phosphorylation and attenuated production of the proangiogenic factors hypoxia-inducible factor and VEGF in these gastric cancer cell.
lines [65]. Everolimus has demonstrated antitumor activity in gastric cancer in preclinical studies [64–66] and a phase I study involving patients with AGC [67]. The results of a phase I study of everolimus in 53 patients with previously treated AGC showed a disease control rate of 56.0% and median PFS of 2.7 months. At a median follow-up duration of 9.6 months, the median OS was 10.1 months and good tolerability was observed [68]. Based on this promising result, a prospective phase III trial of everolimus in previously treated patients with advanced gastric cancer: GRANITE-1 was conducted [69]. A total of 656 patients from 23 countries were enrolled; 439 were randomized to everolimus, 217 to placebo. Median OS was 5.39 months with everolimus vs 4.34 months with placebo (HR, 0.90; 95% CI, 0.75–1.08; P = 0.1244). Median PFS was 1.68 vs 1.41 months (HR, 0.66; 95% CI, 0.56–0.78; p < 0.0001). The most common grade 3/4 adverse events were anemia, decreased appetite and fatigue. Everolimus monotherapy did not significantly improve OS in patients with AGC previously treated with 1 or 2 lines of systemic chemotherapy.

**Future perspectives**

Emerging data from the development of targeted therapy have provided novel strategies that are expected to translate into survival benefits for AGC patients. The results of the ToGA study recently demonstrated that the addition of trastuzumab to chemotherapy can bring survival benefit to HER2-positive AGC patients. However, this benefit is limited to only 20% of AGC patients (HER2-positive). Therefore, there remains a critical need for both the development of more effective agents and the identification of predictive molecular markers to select those patients who might benefit most from specific targeted therapies. Till now both cetuximab and bevacizumab have failed in phase III trial for AGC. The results of pertuzumab and T-DM1 are worth waiting for. The addition of trastuzumab to chemotherapy can bring survival benefit to HER2-positive AGC patients. However, a prospective phase III trial of trastuzumab and T-DM1 is needed.

**Abbreviations**

AGC: Advanced gastric cancer; OS: Overall survival; BSC: Best supportive care; HER2: Human epidermal growth factor receptor-2; EGFR: Epidermal growth factor receptor; VEGF: Vascular endothelial growth factor; HGF: Hepatocyte growth factor; mTOR: Mammalian target of rapamycin; TK: Tyrosine kinase; HR: Hazard ratio; CI: Confidence interval; IHC: Immunohistochemistry; AE: Adverse events; GEJ: Gastroesophageal junction; OS: Overall survival; PFS: Progression free survival; ASCO: American Society of clinical oncology; DCR: Disease control rate; RR: Response rate; PD: Disease progress; PFS: Progression free survival; ASCO: American Society of clinical oncology; HR: Hazard ratio; CI: Confidence interval; IHC: Immunohistochemistry; mTOR: Mammalian target of rapamycin; TK: Tyrosine kinase; VEGF: Vascular endothelial growth factor; HGF: Hepatocyte growth factor; Tyr: Tyrosine.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

All authors have contributed to data preparation, drafting and revising the manuscripts. Both authors have read and approved the final manuscript.

**Received:** 27 August 2013 **Accepted:** 2 December 2013

**Published:** 11 December 2013

**References**

1. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24(14):237–250.

2. Moore MA, Eser S, Igisimov N, Igisimov S, Mohagheghi MA, Mousavi-Jarahi A, Oezturk G, Soiopova M, Tuncer M, Soibue T: Cancer epidemiology and control in North-Western and Central Asia - past, present and future. Asian Pac J Cancer Prev 2010, 11(Suppl 2):17–32.

3. Hao J, Chen WQ: Chinese cancer registry annual report. Beijing: Military Medical Science Press; 2012.

4. Murad AM, Santiago FF, Petrosian A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993, 72(1):37–41.

5. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epirubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995, 71(3):587–591.

6. Cunningham D, Starling N, Rao S, Heuron T, Nicolson M, Coxon M, Middleton G, Daniel F, Oates J, Norman AR: Upper gastrointestinal clinical studies group of the national cancer research institute of the United Kingdom: capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 356(1):37–46.

7. Van Cutsem E, Mojseyenko VM, Tjulandin S, Constenla M, Boni C, Rodrigues A, Fodor M, Choy Y, Vaznyi E, Risse ML, Ajan JA: V325 Study Group: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006, 24(31):4991–4997.

8. Wagner AD, Grothe W, Haerting J, Kleber G, Grothee A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24(18):2903–2909.

9. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Savaki A, Lordick F, Ohtsu A, Yoshitake Y, Saito T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):697–707.

10. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, et al: Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007, 109(4):658–667.

11. Langer R, Von Rahden BH, Nahrig J, Von Weyhern C, Reiter R, Feith M, Stein HJ, Sievert JR, Höffer H, Sarbia M: Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal and esophagogastric junction adenocarcinomas: a tissue microarray study. J Clin Pathol 2006, 59(6):631–634.

12. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH: EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008, 52(6):738–746.

13. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M, Zamboi A, De Vito F, Ferraraccio F: Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007, 31(7):1458–1468.

14. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboi A, De Vito F, Galizia G: Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008, 15(1):59–69.

15. Hsieh AC, Moasser MM: Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007, 97(4):453–457.
21. Gómez-Martín C, Garralda E, Echarri MJ, Ballesteros A, Arcediano A, HER2 as a prognostic marker in gastric cancer -
23. Jørgensen JT, Hersom M:
17. Toikkanen S, Helin H, Isola J, Joensuu H:
16. Lian L, Ning W, Jin L:
Qiu and Xu
Advanced HER2-positive gastric cancer: current
22. Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, Liu JP, Bu H, Zhou XY,
31. Hecht JR, Bang Y, Qin S, Chung H, Xu J, Park J, Jeziorski K, Shparyk Y, Hoff
29. Kim JG:
Molecular targeted therapy for advanced gastric cancer.
Br J Cancer
Chinese representative clinical centers and assessment of its prognostic
HER2 status in gastric cancers: a retrospective analysis from four
2012, 5(8):513–519.
2012,
2010, 10(7):1044–1048.
Sethadi R, Horsfall DJ, Fargala F, McCaul K, Setvar Y, Chalmers AH, Yeo R,
1987, 253(7):177–182.
2011, 56(1):61–65.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987, 235(4785):177–182.
J Clin Pathol 2012, 65(8):751–757.
D M, Hidalgo M, López-Nicos F: HER2/neu testing for anti-Herb2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol 2010, 63(5):488–492.
2012, 22(8):1317–144.
2013, 30(4):369–376.
Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor-2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010, 28(7):1138–1144.
2006, 28(14):1594–1600.
Tabernerio J, Hoff PM, Shen L, Ohtsu A, Yu R, Eng-Wong J, Kang YK: Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB) [abstract]. J Clin Oncol 2013, 31(7):TPS5410. http://www.worldonc.org.
2013, 17(20):6437–6447.
2013, 28(2):149–155.
2012, 30(4):1594–1600.
Kim KS: Molecular targeted therapy for advanced gastric cancer. Korean J Intern Med 2013, 28(2):149–155.
2010, 100(3):298–304.
Moehler M, Mueller A, Tratbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwartz S, Galle PR, Kanzler S: German Arbeitsgemeinschaft Internistische Onkologie. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastric cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 2011, 22(10):1358–1366.
2012, 32:1.
19. Toikkanen S, Helin H, Isola J, Joensuu H:
20. Heinrich CP, Eisenhauer EA, Blanke C, van Oosterom AT, Stadler WM, Van Cutsem E, et al: Recommendations for guidelines on the use of targeted agents in cancer therapy. Br J Cancer 2010, 103(6):804–811.
24. Fuchs CS, Tomasek J, Cho JY, Dumitru F, Passalacqua R, Goswami C, Safran PM, Sobrero AF, http://www.asco.org/.
28. Kim SE, Shin KM, Jung SA, Yoo K, Lee SH: The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver 2009, 3(2):88–94.
27. Waddell T, Chau I, Cunningham D, Gonzalez D, Okeines AF, Okeines W, Wootenpsoon A, Saferly C, Middleton G, Wadley J, et al: Eribulin, oxaliplatin, and cetuximab with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3), a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14(6):490–499.
26. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77(5):858–863.
25. Kim SE, Shin KM, Jung SA, Yoo K, Lee SH: The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver 2009, 3(2):88–94.
24. Fuchs CS, Tomasek J, Cho JY, Dumitru F, Passalacqua R, Goswami C, Safran PM, Sobrero AF, et al: Recommendations for guidelines on the use of targeted agents in cancer therapy. Br J Cancer 2010, 103(6):804–811.
28. Kim SE, Shin KM, Jung SA, Yoo K, Lee SH: The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver 2009, 3(2):88–94.
27. Waddell T, Chau I, Cunningham D, Gonzalez D, Okeines AF, Okeines W, Wootenpsoon A, Saferly C, Middleton G, Wadley J, et al: Eribulin, oxaliplatin, and cetuximab with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3), a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14(6):481–489.
26. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77(5):858–863.
25. Kim SE, Shin KM, Jung SA, Yoo K, Lee SH: The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver 2009, 3(2):88–94.
27. Waddell T, Chau I, Cunningham D, Gonzalez D, Okeines AF, Okeines W, Wootenpsoon A, Saferly C, Middleton G, Wadley J, et al: Eribulin, oxaliplatin, and cetuximab with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3), a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14(6):481–489.
25. Kim SE, Shin KM, Jung SA, Yoo K, Lee SH: The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver 2009, 3(2):88–94.
27. Waddell T, Chau I, Cunningham D, Gonzalez D, Okeines AF, Okeines W, Wootenpsoon A, Saferly C, Middleton G, Wadley J, et al: Eribulin, oxaliplatin, and cetuximab with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3), a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14(6):481–489.
25. Kim SE, Shin KM, Jung SA, Yoo K, Lee SH: The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver 2009, 3(2):88–94.
27. Waddell T, Chau I, Cunningham D, Gonzalez D, Okeines AF, Okeines W, Wootenpsoon A, Saferly C, Middleton G, Wadley J, et al: Eribulin, oxaliplatin, and cetuximab with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3), a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14(6):481–489.
25. Kim SE, Shin KM, Jung SA, Yoo K, Lee SH: The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver 2009, 3(2):88–94.
27. Waddell T, Chau I, Cunningham D, Gonzalez D, Okeines AF, Okeines W, Wootenpsoon A, Saferly C, Middleton G, Wadley J, et al: Eribulin, oxaliplatin, and cetuximab with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3), a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14(6):481–489.
25. Kim SE, Shin KM, Jung SA, Yoo K, Lee SH: The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver 2009, 3(2):88–94.
27. Waddell T, Chau I, Cunningham D, Gonzalez D, Okeines AF, Okeines W, Wootenpsoon A, Saferly C, Middleton G, Wadley J, et al: Eribulin, oxaliplatin, and cetuximab with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3), a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14(6):481–489.
50. Li J, Qin S, Xu J, Guo WJ, Xiong JP, Bai Y, Sun G, Yang Y, Wang L, Xu N, et al: A randomized, double-blind, multicenter, phase, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma [abstract]. J Clin Oncol 2011, 29(Suppl):4019.

51. Sharma T, Dhingra R, Singh S, Sharma S, Tomar P, Mahnot M, Bhadwaj TR: Avelumab: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors. Mini Rev Med Chem 2013, 13(4):530–540.

52. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Gurova E, et al: VEGF Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99(17):11393–11398.

53. Konner J, Dupont J: Use of soluble recombinant decoy VEGF trap to inhibit VEGF activity. Clin Colorectal Cancer 2004, 4:581–585.

54. Lassoued W, Murphy D, Tsi J, Oueslati R, Thurston G, Lee W: Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Cancer Biol Ther 2011, 10(12):1326–1333.

55. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R: Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002, 13(1):41.

56. Galland F, Stefanova M, Lafage M, Birnbaum D: Localization of the 5’end of the MCF2 oncogene to human chromosome 15q15–q23. Cyto genet Genome Res 1992, 60(2):114–116.

57. Comoglio PM, Giordano S, Trusolino L: Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008, 7(6):504–516.

58. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Saikaguchi T, Hirao T, Nakano H, et al: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999, 85(9):1894–1902.

59. Dussault I, Bellon SF: From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anti-Cancer Agents Med Chem 2009, 9(2):221–229.

60. Earthing S, Palma R, Volckova E, Hisch M, France DS, Ashwell MA, Chan TC: Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 2011, 286(23):20666–20676.

61. Underliner TL, Herbertz T, Michaylozcy S: Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anti-Cancer Agents Med Chem 2010, 10(1):7.

62. Choueiri TK, Valshpamyan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, et al: Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 2011, 286(23):20666–20676.

63. Van Cutsem E, Yeh KH, Bang YJ, et al: Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer [AGC]: GRANITE-1[abstract]. J Clin Oncol 2012(Suppl 4):11B1A3. http://www.asco.org/.

64. Doi T, Muro K, Boku N, Yamada Y, Okumura T, Hattori R, Komatsu Y, Hamamoto Y, Oho N, Fujita Y, et al: Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010, 28(11):1904–1910.

65. Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Lesokhin AM, Grob S, Fuereder T, Wacheck V: Everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1[abstract]. J Clin Oncol 2012(Suppl 4):11B1A3. http://www.asco.org/.